Susan F. Slovin, MD, PhD, discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC to determine if the combination is effective in castration-resistant patients.
Dr. Slovin is an attending physician at the Sidney Kimmel Center for Prostate and Urologic Cancers
at Memorial Sloan Kettering Cancer Center, and is a professor of medicine at Weill Cornell Medical College.